At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ELAB PMGC Holdings
Post-Mkt 09-03 19:57:14 EDT
5.23
+0.14
+2.75%
盘后5.11
-0.12-2.21%
19:40 EDT
High5.39Low5.01Vol26.07K
Open5.16D1 Closing5.09Amplitude7.37%
Mkt Cap4.23MTradable Cap4.00MTotal Shares809.58K
T/O135.07KT/O Rate3.41%Tradable Shares764.19K
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

PMGC Holdings advances AI-driven cardiometabolic expansion program
TIPRANKS  ·  09-03 05:58
PMGC Holdings advances AI-driven cardiometabolic expansion program
U.S. Stocks on the MOVE-GoPro, TXNM Energy, Emergent BioSolutions
Reuters  ·  09-01 23:48
U.S. Stocks on the MOVE-GoPro, TXNM Energy, Emergent BioSolutions
PMGC Unit NorthStrive Biosciences Expands AI Drug Discovery Program with Yuva Biosciences
Reuters  ·  09-01 19:45
PMGC Unit NorthStrive Biosciences Expands AI Drug Discovery Program with Yuva Biosciences
Northstrive Biosciences - Amendment Grants Co Right of First Refusal for Exclusive License in Cardiometabolic Field
THOMSON REUTERS  ·  09-01 19:45
Northstrive Biosciences - Amendment Grants Co Right of First Refusal for Exclusive License in Cardiometabolic Field
Northstrive Biosciences Expands AI-Driven Drug Discovery Program with Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination for Potential Cardiac Disease and Obesity Therapeutic Applications
THOMSON REUTERS  ·  09-01 19:45
Northstrive Biosciences Expands AI-Driven Drug Discovery Program with Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination for Potential Cardiac Disease and Obesity Therapeutic Applications
Northstrive Biosciences - Expansion Program Expected to Take 6 Months and Culminate in Lead Compound Nomination
THOMSON REUTERS  ·  09-01 19:45
Northstrive Biosciences - Expansion Program Expected to Take 6 Months and Culminate in Lead Compound Nomination
PMGC Plans CAD 200,000 Orbit2Orbit Share Subscription at CAD 0.8 Per Share
Reuters  ·  08-28
PMGC Plans CAD 200,000 Orbit2Orbit Share Subscription at CAD 0.8 Per Share
PMGC terminates non-binding letter of intent to acquire Arizona company
TIPRANKS  ·  08-26
PMGC terminates non-binding letter of intent to acquire Arizona company
PMGC Holdings Terminates LOI to Buy 76% Stake in Arizona Precision Machining Company
Reuters  ·  08-26
PMGC Holdings Terminates LOI to Buy 76% Stake in Arizona Precision Machining Company
Pmgc - Incurs no Breakup Fee or Termination Penalty for Loi Termination
THOMSON REUTERS  ·  08-26
Pmgc - Incurs no Breakup Fee or Termination Penalty for Loi Termination
Pmgc Holdings Terminates Previously Announced Acquisition Loi Following Due Diligence Review; Reaffirms Disciplined M&a Strategy and Expands Investment Across Aerospace & Defense Manufacturing Portfolio
THOMSON REUTERS  ·  08-26
Pmgc Holdings Terminates Previously Announced Acquisition Loi Following Due Diligence Review; Reaffirms Disciplined M&a Strategy and Expands Investment Across Aerospace & Defense Manufacturing Portfolio
PMGC Holdings Terminates Previously Announced Acquisition LOI Following Due Diligence Review; Reaffirms Disciplined M&A Strategy and Expands Investment Across Aerospace & Defense Manufacturing Portfolio
GlobeNewswire  ·  08-26
PMGC Holdings Terminates Previously Announced Acquisition LOI Following Due Diligence Review; Reaffirms Disciplined M&A Strategy and Expands Investment Across Aerospace & Defense Manufacturing Portfolio
PMGC Signs Term Sheet with Orbit2Orbit for NorthStrive Microgravity Muscle-Loss Study
Reuters  ·  08-25
PMGC Signs Term Sheet with Orbit2Orbit for NorthStrive Microgravity Muscle-Loss Study
Pmgc Holdings Announces Term Sheet with Orbit2orbit for Northstrive Biosciences to Launch a Spaceflight Study of Its Myostatin and Activin a Assets, El-22 and El-32, Targeting Microgravity-Induced Muscle Loss
THOMSON REUTERS  ·  08-25
Pmgc Holdings Announces Term Sheet with Orbit2orbit for Northstrive Biosciences to Launch a Spaceflight Study of Its Myostatin and Activin a Assets, El-22 and El-32, Targeting Microgravity-Induced Muscle Loss
PMGC Unit NorthStrive Biosciences Files US Patents for EL-22, EL-32 to Curb Microgravity Muscle Loss
Reuters  ·  08-21
PMGC Unit NorthStrive Biosciences Files US Patents for EL-22, EL-32 to Curb Microgravity Muscle Loss
Northstrive Biosciences Announces the Filing of Two U.S. Patent Applications Targeting Microgravity-Induced Muscle Loss During Long-Duration Spaceflight
THOMSON REUTERS  ·  08-21
Northstrive Biosciences Announces the Filing of Two U.S. Patent Applications Targeting Microgravity-Induced Muscle Loss During Long-Duration Spaceflight
PMGC announces 1-for-10 reverse stock split
TIPRANKS  ·  08-19
PMGC announces 1-for-10 reverse stock split
PMGC to Execute 1-for-10 Reverse Stock Split on Aug. 21
Reuters  ·  08-19
PMGC to Execute 1-for-10 Reverse Stock Split on Aug. 21
Pmgc - to Effect 1-for-10 Reverse Stock Split Effective August 21, 2026
THOMSON REUTERS  ·  08-19
Pmgc - to Effect 1-for-10 Reverse Stock Split Effective August 21, 2026
PMGC Q2 FY26 Net Loss Widens to $2.96 Million; Revenue Turns Positive to $1.31 Million
Reuters  ·  08-14
PMGC Q2 FY26 Net Loss Widens to $2.96 Million; Revenue Turns Positive to $1.31 Million
No data available

Introduction

Company Name.
PMGC Holdings
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.
Issue price:
--